Dear Research Community,
As the Autumn season marks the transition from Summer to Winter, it is a fitting metaphor for the changes to Carilion Clinic Research. On May 15th, Andrea Bidanset and I started our new roles as director of clinical trials and senior director of research and development, respectively. Andrea ascended into her role after several years as a clinical research coordinator while I transitioned from a career as a research scientist in the pharmaceutical industry. In common, we grew up in the Roanoke Valley albeit decades apart. Over the last few months, we have been on a listening tour to gather information, suggestions, and criticisms of our department. I would encourage you to complete our survey so that we quantify your comments. Secondly, we want to ascertain your expectations of the department and query your opinion on new services we hope to provide in the future. Please briefly review the newsletter to learn about some of the changes to Research and Development including changes to the Research Acceleration Program and the introduction of REDCap.
In addition to new leadership in the Department of Research and Development, I want to note other changes that impact research. Carley Emerson has been named the new director of the Institutional Review Board (IRB). She replaces Chuck Hite, who retired on September 1. Also, Min Wang will join the Health Analytics team supporting research projects. Please read more about Carley and Min in the Notables section.
Francis X. Farrell, PhD